Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2022 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: sjemmeri who wrote (135)	6/11/2022 10:19:21 AM
From: technetium	Read Replies (1) \| Respond to of 267

Re: BLUE It didn’t do well last year, which why people probably stayed away, and it hasn’t done well this year either. However, good news could be around the corner: bizjournals.com “In a second key win for the embattled biotech, bluebird bio Inc. has scored two endorsements in as many days from an advisory committee to the U.S. Food and Drug Administration, suggesting it could become a commercial-stage biotech in just a few months. “On Friday, the committee voted unanimously in favor of an approval for beti-cel, bluebird's (Nasdaq: BLUE) gene therapy for the blood disorder beta thalassemia in patients who are transfusion-dependent. The vote came a day after another unanimous endorsement by the same committee for eli-cel, which is designed to treat the neurological disorder cerebral adrenoleukodystrophy (ALD).“